BVNK.F Stock Overview
Develops, manufactures, and supplies life-saving vaccines. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Bavarian Nordic A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 26.80 |
| 52 Week High | DKK 46.05 |
| 52 Week Low | DKK 20.71 |
| Beta | 1.21 |
| 1 Month Change | 23.28% |
| 3 Month Change | 8.70% |
| 1 Year Change | 18.11% |
| 3 Year Change | 3.12% |
| 5 Year Change | 68.66% |
| Change since IPO | -22.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| BVNK.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | 5.0% | 0.5% |
| 1Y | 18.1% | -11.6% | 11.1% |
Return vs Industry: BVNK.F exceeded the US Biotechs industry which returned -13.8% over the past year.
Return vs Market: BVNK.F exceeded the US Market which returned 11.7% over the past year.
Price Volatility
| BVNK.F volatility | |
|---|---|
| BVNK.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: BVNK.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine BVNK.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,645 | Paul Chaplin | www.bavarian-nordic.com |
Bavarian Nordic A/S develops, manufactures, and supplies life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; Vaxchora, an oral vaccine for immunization against cholera; and Vivotif/Typhoral, an oral vaccine for immunization against typhoid fever. It is also developing MVA-BN WEV for the treatment of encephalitis viruses.
Bavarian Nordic A/S Fundamentals Summary
| BVNK.F fundamental statistics | |
|---|---|
| Market cap | US$1.99b |
| Earnings (TTM) | US$199.10m |
| Revenue (TTM) | US$939.05m |
Is BVNK.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BVNK.F income statement (TTM) | |
|---|---|
| Revenue | DKK 6.23b |
| Cost of Revenue | DKK 3.00b |
| Gross Profit | DKK 3.23b |
| Other Expenses | DKK 1.91b |
| Earnings | DKK 1.32b |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 22, 2025
| Earnings per share (EPS) | 16.97 |
| Gross Margin | 51.90% |
| Net Profit Margin | 21.20% |
| Debt/Equity Ratio | 0.1% |
How did BVNK.F perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/20 07:59 |
| End of Day Share Price | 2025/05/12 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Bavarian Nordic A/S is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Ankersen | ABG Sundal Collier |
| Jacob Lademann | Carnegie Investment Bank AB |
| Peter Verdult | Citigroup Inc |